Core Viewpoint - Marvel Biosciences Corp. is sponsoring the 3rd European Purine Meeting to foster scientific exchanges and connections in the field of purinergic signaling, which is crucial for understanding various neurological disorders [1][2]. Company Overview - Marvel Biosciences Corp., through its subsidiary Marvel Biotechnology Inc., is focused on developing novel therapies for neurological and neurodevelopmental disorders, with its lead drug candidate being MB-204, a derivative of Istradefylline [4]. - The company is exploring the potential of MB-204 in treating conditions such as autism, depression, Alzheimer's disease, and rare disorders like Rett syndrome and Fragile X syndrome [5]. Industry Insights - The purinergic system plays a vital role in numerous physiological functions, and its dysregulation is linked to diseases such as Alzheimer's and autism [2]. - The A2A receptor, a target for MB-204, is gaining commercial interest as a neurological target beyond its original development for Parkinson's Disease [3].

Grail, an American biotech company, has an ambitious goal: to develop a blood test for the early detection of 50 types of cancer. It will not be easy https://t.co/IJVlgTJRgBPhoto: Science Photo Library https://t.co/eOSXxU8cMZ ...

Core Viewpoint - Carbios is facing destabilization efforts from a former executive, leading the company to contest all allegations and file a criminal complaint for false accusations [1][2][3]. Company Response - The executive management and Board of Directors of Carbios express their disapproval of the former executive's actions, which they believe are motivated by personal grievances related to his departure [3]. - The Board of Directors has unanimously reaffirmed its support for the executive management team, emphasizing their trust in the ongoing strategic implementation [4]. Company Overview - Carbios is a biotechnology company focused on developing biological solutions for plastics and textiles, aiming to prevent pollution and promote a circular economy [5]. - The company is advancing two key technologies: PET biorecycling and PLA biodegradation, which are currently being scaled to industrial levels [5]. - Carbios collaborates with notable brands in various industries, including Nestlé Waters, PepsiCo, and L'Oréal, to enhance product recyclability [5].

A Leading Specialty Vaccine Company March 2026 Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Valneva is a European company. Information distributed is subject to European disclosure requirements that are different from those of the United States. Financial statements and information may be prepared ac ...

Core Viewpoint - Exelixis is a commercial-stage, oncology-focused biotech company that has successfully established its first franchise with cabozantinib and aims to expand its pipeline of franchises [1]. Group 1 - The company has been operational for a significant period and believes it has reached a pivotal point in building its franchises [1]. - Exelixis held an R&D Day in December to discuss strategies for developing a pipeline of franchises and the multi-dimensional approach to franchise building [2].

Core Viewpoint - Quantum-Si, Inc. reported a quarterly loss and missed revenue estimates, leading to a decline in stock price during extended trading hours [1][4]. Financial Performance - The company reported a quarterly loss of 8 cents per share, which was better than the Street estimate of a loss of 12 cents [2]. - Quarterly revenue was $451,000, falling short of the analyst estimate of $762,000 [2]. - The company announced a list price for its Proteus system at $425,000 [2]. Strategic Progress - The CEO highlighted significant progress in 2025, including advancements in technology through new kit launches and increased utilization of the first-generation Platinum Pro system [3]. - The company achieved its strategic goal of demonstrating sequencing on the Proteus prototype system, surpassing current technology across key performance metrics [3]. Future Outlook - Quantum-Si expects fiscal 2026 revenue to be $1 million, significantly lower than the $7.15 million estimate [4]. - Following the earnings report, Quantum-Si's stock price decreased by 4.51% to 90 cents in extended trading [4].

Core Insights - Tonix Pharmaceuticals Holding Corp. announced a poster presentation for its product Tonmya™ (cyclobenzaprine HCl sublingual tablets) at the 2026 AAPM PainConnect Annual Meeting, highlighting its significance in treating fibromyalgia [1][3]. Company Overview - Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments, addressing areas of high unmet medical need [3]. - The company’s flagship medicine, Tonmya, is the first new treatment for fibromyalgia in over 15 years [3]. - Tonix's CNS commercial infrastructure supports marketed products, including acute migraine treatments Zembrace® SymTouch® and Tosymra® [3]. Product Development - Tonix is conducting Phase 2 clinical trials to evaluate Tonmya's potential in major depressive disorder and acute stress disorder [3]. - The company is advancing TNX-2900, which is Phase 2 ready for treating Prader-Willi syndrome, a rare disease [3]. - Tonix is also developing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection [3].

PresentationTyler Van BurenTD Cowen, Research Division All right. Okay. Good afternoon, everyone. Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For this next session, it's a privilege to be hosting a fireside chat with Moderna management. And from Moderna, it's my pleasure to introduce Jamey Mock, Chief Financial Officer of Moderna. Jamey, so great to have you. Thank you for joining me. ...

Summary of Alector, Inc. Conference Call Company Overview - **Company**: Alector, Inc. - **Event**: 46th Annual TD Cowen Healthcare Conference - **Focus**: Presentation on the ABC platform and its applications in drug development, particularly for neurological diseases Key Points ABC Platform and Technology - Alector has developed an Antibody-Based Carrier (ABC) platform over the past seven years, focusing on blood-brain barrier (BBB) technology to enhance drug delivery to the brain [2][3] - The platform utilizes transferrin receptor (TFR) as a target for delivering various therapeutic cargos, including antibodies, enzymes, and siRNAs [3][4] - Alector has successfully applied ABC technology to 13 different cargos, demonstrating its versatility in drug delivery [4][5] Lead Programs - **Lead Antibody Candidate**: An anti-amyloid antibody enabled by ABC technology, designed to enhance brain uptake while minimizing safety liabilities [13][14] - **GCase Enzyme Program**: Targeting GBA-related Parkinson's disease, Alector has engineered a GCase enzyme that is 50 times more active than the wild-type enzyme, with improved stability [22][23][24] - **siRNA Platform**: Alector is also developing siRNA therapeutics using the ABC platform, targeting diseases like tauopathies and alpha-synucleinopathies [29][30] Efficacy and Safety Data - The anti-amyloid antibody demonstrated a 30-32 fold increase in brain uptake compared to naked antibodies, with significant safety improvements observed in non-human primate studies [19][20][21] - The GCase enzyme showed a 100% increase in enzymatic activity in wild-type mice, with sustained reduction of toxic substrates observed over four weeks [25][26][27] - siRNA therapeutics showed strong brain accumulation and effective knockdown of target mRNA, with no adverse events reported even at high doses [36] Clinical Development Plans - Alector plans to submit an Investigational New Drug (IND) application by the end of 2023 or early 2024, with initial studies in healthy volunteers and patients with early Alzheimer's disease [42][43] - The clinical trial will focus on demonstrating amyloid clearance using amyloid PET imaging, with a goal of enrolling 10 to 15 patients for initial readouts [43][44] Interim Analysis for AL101 - An interim futility analysis for the AL101 candidate is scheduled for the first half of the year, with results expected to guide the continuation or cessation of the study [45][46] Additional Insights - Alector emphasizes the importance of maintaining fully active effector functions in their antibody designs to ensure therapeutic efficacy [14][15] - The company is focused on achieving subcutaneous administration for all its programs, which would enhance patient convenience and compliance [38][39] - Alector's approach to drug development is characterized by a commitment to safety, as evidenced by the lack of adverse events in their studies [29][36]

Summary of Centessa Pharmaceuticals FY Conference Call Company Overview - **Company**: Centessa Pharmaceuticals (NasdaqGS:CNTA) - **Focus**: Development of orexin antagonists for the treatment of narcolepsy and other neurodegenerative disorders Key Points Progress and Goals - Transition to CEO has been marked by significant progress since the company's founding in 2019, particularly with the drug ORX-750 aimed at treating rare hypersomnias [3][4] - The company aims to build a multi-asset franchise targeting multiple indications with orexin antagonists, positioning itself as a leader in orexin biology [4][7] Clinical Data and Efficacy - Data disclosed in November showed promising results for ORX-750, with a greater than 20-minute improvement in the Maintenance of Wakefulness Test (MWT) for narcolepsy Type 1 (NT1) and over 10 minutes for narcolepsy Type 2 (NT2) [6][7] - The Epworth Sleepiness Scale (ESS) scores improved significantly, indicating normalization of symptoms [7][21] - The company is focused on achieving a best-in-class profile, particularly in terms of prolonged efficacy and tolerability [19][20] Phase 2 Study Updates - An update on the Phase 2 study is expected in Q1, with potential data across multiple indications [9][10] - The registrational program is set to begin this quarter, with a focus on at least one indication [10][12] Differentiation and Mechanism of Action - Centessa emphasizes the unique mechanism of action of its orexin agonists, which restore normal wakefulness and show significant efficacy compared to current standard care [15][16] - The company aims to differentiate its product through prolonged duration of action and improved tolerability profiles [18][19] Safety and Tolerability - The drug has shown a favorable safety profile, with no significant adverse events limiting the therapeutic index [39][40] - Visual disturbances reported were mild and transient, with no dose-response relationship observed [44][45] Future Directions - Centessa plans to initiate additional studies in other indications, focusing on proof of concept [55] - The company is preparing for commercial readiness, including hiring a commercial team and enhancing communication strategies to raise awareness among clinicians [57] Broader Opportunities - Beyond narcolepsy, Centessa sees potential in addressing symptoms of broader neuropsych and neurodegenerative disorders, leveraging its multi-asset orexin agonist franchise [52][53] Engagement with Regulatory Bodies - The company has had multiple interactions with the FDA, indicating good alignment on its registration program [50] Additional Insights - The company is committed to educating a wider range of healthcare professionals about its products and the conditions they address, moving towards a pre-commercial stage [56][57]